Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

Conference Call on Wednesday, March 11, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, March 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), today announced its fourth quarter and fiscal year 2008 financial results, reviewed the Company's highlights and provided an outlook for 2009.

"2008 was a tremendously active year from an execution standpoint as we took measures to prepare for the final stages of clinical development of our lead product candidate, OGX-011, for the treatment of cancer and to position for long term growth of the Company," said Scott Cormack, President and Chief Executive Officer of OncoGenex. "We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are working closely with the FDA to develop Phase 3 study designs and protocols defining a registration path for product approval. We also took measures to extend our cash runway, and we have been advancing discussions with potential development partners."

    Key Objectives for 2009

    -   Report final survival data with additional results from the Phase 2
        clinical trial evaluating first-line docetaxel with and without
        OGX-011 treatment in patients with castrate resistant prostate cancer
        ("CRPC"); these data have been selected for presentation at the
        American Society of Clinical Oncology 2009 Annual Meeting in the
        second quarter.
    -   In the second quarter, reach an agreement with the FDA via the
        Special Protocol Assessment process ("SPA") on the design of a second
        Phase 3 registration trial evaluating durable pain palliation for
        OGX-011 in combination with docetaxel as second-line chemotherapy in
        patients with CRPC.
    -   In the third quarter, discuss w
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... ... The global aptamers market is expected to reach $244.93 ... 17.89% between 2015 and 2020. The aptamer type segments included in this report ... is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications will ...
(Date:7/6/2015)... ... July 06, 2015 , ... An optical technology ... how blood flows in the brain during stroke, providing information that could someday ... article published in the journal Neurophotonics describes work at the University ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters were ... high-end machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or a ... that even NIST used them for their SRM-2031 series going back for many years. ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3
...
... , , , , , ... quantitative analysis of nucleic acids , and proteins has ... It includes absorption measurements in the ultraviolet and in the visibility , ... at 260 , nm and colorimetric protein determination is ...
... for Improving QPCR , , ... available QPCR machines with , ... offers better performance and ... allows researchers to quickly and easily,quantify nucleic acids for studying gene ...
Cached Biology Technology:Quantification made easy 2Quantification made easy 3Mx4000 Multiplex Quantitative PCR System*,PPP 2Mx4000 Multiplex Quantitative PCR System*,PPP 3Mx4000 Multiplex Quantitative PCR System*,PPP 4
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards (FPC) ... that it will amount to at least 340 MSEK to ... the rapid increase in market growth and orders received the ... guidance that revenue for 2015 will exceed 1,500 MSEK to ... approximately 2,200 MSEK. Due to receipt of orders ...
(Date:6/15/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces that its leading payment security technology, ... Digital Experience! @ NYC June 18th. Digital Experience! ... innovation in technology to over 300 of the top media ... Metropolitan Pavilion in New York City ...
(Date:6/10/2015)... 10, 2015 According to ... by Technology (Ultrasound, TOF, Structured Light, Stereo Vision), ... Automotive) and by Geography - Trends & Forecast ... market is expected to reach $3,319.71 Million by ... 2015 and 2020. Browse 71 market ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... step in developing a cost-effective micro sensor for long-term ... team of scientists and engineers. The new technology, ... by engineers from the National Oceanography Centre, in close ... Earth Science, which is based at the centre. ...
... Ill. , Nov. 13, 2013  Baxter International Inc. ... III clinical trial of BAX 855, an investigational extended ... The ongoing trial is aimed at assessing the efficacy ... in both prophylaxis and on-demand treatment schedules, and will ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
Cached Biology News:New generation of micro sensors for monitoring ocean acidification 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 3Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 4Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 5Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 6Researcher finds potential new use for old drugs 2
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
96 Well Base Plate...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
Biology Products: